欢迎访问西安瑞禧生物技术有限公司官方网站

图片名

全国订购热线:
18966759382

首页 > 新闻资讯 > 市场活动

市场活动
行业新闻 市场活动 技术资讯

trans-Isoferulic acid-d3「同位素标记抑制剂」

作者:瑞禧生物 发布时间:2025-06-12 10:07:45 次浏览

生物活性:trans-Isoferulic acid-d3 is the deuterium labeled trans-Isoferulic acid[1]. trans-Isoferulic acid (trans-3-Hydroxy-4-methoxycinnamic acid) is an aromatic acid isolated from the roots of Clematis florida var. plena. trans-Isoferulic acid exhibits anti-inflammatory activity[2].trans-isoferulic acid suppresses NO and PGE2 production through the induction of Nrf2-dependent heme oxygenase-1 (HO-1)[3].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
trans-Isoferulic acid-d3 相关抗体:
iNOS Antibody
nNOS Antibody
eNOS Antibody
Phospho-eNOS (Ser1177) Antibody
DDAH2 Antibody (YA1447)
Prostaglandin D Synthase Antibody (YA1739)
DDAH1 Antibody (YA2661)
DP1 Antibody (YA2766)
分子量:197.20
Formula:C10H7D3O4
CAS 号:1028203-97-5
非标记 CAS:25522-33-2
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (528 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Kai-Hui Sun, et al. A new indole-type alkaloid from the roots of Clematis florida var. plena. Nat Prod Res. 2019 Oct;33(20):2925-2931.
 [Content Brief]
[3]. Matharage Gayani Dilshara, et al. Downregulation of NO and PGE2 in LPS-stimulated BV2 microglial cells by trans-isoferulic acid via suppression of PI3K/Akt-dependent NF-κB and activation of Nrf2-mediated HO-1. Int Immunopharmacol. 2014 Jan18(1):203-11.
 [Content Brief]